Skip to Content

'
Robert Z Orlowski, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Robert Z. Orlowski, MD, PhD, is Director of Myeloma, and Professor of Medicine

in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division

of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in

Houston, Texas. He is board-certified in internal medicine and medical oncology.

Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry

from Yale University and his medical degree from the Yale University School

of Medicine. He completed his internship and residency in Internal Medicine

at Barnes Hospital at the Washington University in St. Louis School of Medicine.

Dr. Orlowski has published numerous book chapters, articles, and abstracts

on cancer therapy, with a focus on the molecular pathogenesis of oncologic

disease processes and the mechanisms of action of chemotherapeutics.

 

Research Interests

His clinical research efforts focus on the translation of promising laboratory based

findings into novel clinical trials for patients with hematologic

malignancies. He has published in, and is a reviewer for, several journals,

including Blood, Cancer Research, Journal of Clinical Oncology, and the

New England Journal of Medicine. He has received several awards, including

The Leukemia & Lymphoma Society Scholar in Clinical Research and the

Jefferson-Pilot Fellowship in Academic Medicine.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Department of Lymphoma/Myeloma
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2042
Phone: 713-792-2860
Fax: 713-563-5067
Email: rorlowsk@mdanderson.org

Education & Training

Degree-Granting Education

1990 Yale University School of Medicine, New Haven, CT, PHD, Molecular Biophysics & Biochemistry
1983 Columbia College, Columbia University, New York, NY, BA, Chemistry

Postgraduate Training

7/1995-6/1998 Postdoctoral Fellowship, Adult Hematology, Johns Hopkins School of Medicine, Baltimore, MD, Dr. Chi V Dang
9/1994-6/1998 Postdoctoral Fellowship, Medical Oncology, Johns Hopkins Oncology Center, Baltimore, MD, Dr. Ross C Donehower
6/1991-6/1994 Internship and Residency, Internal Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, Drs. William E Clutter, Daniel M Goodenberger

Board Certifications

1997 American Board of Internal Medicine
1994 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2011
Associate Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2011
Lenvel Lee Rothrock Associate Professor, Pharmacology, Hematology/Oncology, The University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 11/2006-8/2007
Associate Professor, Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 6/2005-11/2006
Associate Professor, Medicine, Hematology/Oncology, The University of North Carolina and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 4/2005-11/2006
Assistant Professor, Medicine, Hematology/Oncology, The University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 7/1998-3/2005

Administrative Appointments/Responsibilities

Disease Site Liaison to the International Center, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-present
Director, Section of Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-present
Member, Lineberger Comprehensive Cancer Center, The University of North Carolina At Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007
Member, Molecular Therapeutics Program, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007
Member, Clinical Research Program, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007

Other Appointments/Responsibilities

Member, Medical Advisory Committee, Leukemia & Lymphoma Society, Texas Gulf Coast Chapter, Houston, TX, 1/2015-present
Scientific Advisory Board Member, Myeloma Crowd Research Initiative, Houston, TX, 1/2015-present
Faculty Member, U.S. News & World Report Reputation Workgroup, Houston, TX, 8/2014-present
Chair, SWOG Search Committee for Lymphoma, Houston, TX, 1/2014-present
Member, AACR Clinical and Translational Cancer Research Grants Scientific Review Committee, Houston, TX, 1/2014-4/2015
Member, Millennium Independent Data Monitoring Committee for C16019 Ixazomib post-transplant MM maintenance study, Houston, TX, 2014-present
Member, SWOG - Social Media Working Group, Houston, TX, 10/2013-present
Presenter, SWOG Fall Meeting 2013 Plenary Session, Best of SWOG Update: Myeloma, Chicago, IL, 10/2013
Member, NCI Cancer Drug Development Grant Review Committee, Bethesda, MD, 7/2013-present
Leader, SWOG Search Committee for Leukemia, Houston, TX, 10/2012-present
Chairman, Millennium Independent Data Monitoring Committee (IDMC) for C16010 Study, Houston, TX, 10/2012-present
Member, Celgene Sponsored - Pomalidomide Independent Adjudication Committee, Paris, France, 3/2012-present
Member, American Cancer Society - Cancer Drug Discovery Committee, Atlanta, GA, 1/2012-12/2015
Chair, SWOG Group/Barlogie Multiple Myeloma Committee, Houston, TX, 2011-present
Member, National Cancer Institute Myeloma Steering Committee (MYSC), Houston, TX, 2010-present
Member, Editorial Board, Journal of Clinical Oncology, Houston, TX, 2009-present
Member, Editorial Board, Expert Review of Hematology, Houston, TX, 2008-present
Member, American Society of Hematology Scientific Committee on Lymphoid Neoplasia, Houston, TX, 2006-2011
Member, Cancer and Leukemia Group B Leukemia Core Committee, Chapel Hill, NC, 1/2005-1/2008
Member, American Society for Biochemistry and Molecular Biology/ FASEB Member, Houston, TX, 2002-present

Endowed Positions

Lenvel Lee Rothrock Associate Professor in Medicine and Pharmacology, Medicine, Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 11/2006-8/2007

Institutional Committee Activities

Reviewer, Division of Cancer Medicine Annual Research Awards Committee, 8/2013-present
Member, BMT CTN SOSS Myeloma Committee, 5/2013-present
Member, Promotion and Tenure Committee, 1/2013-8/2015
Executive Council Member, SWOG Executive Council Meeting, 9/2012-present
Committee Member, GAP Recurring Africa Steering Committee, 7/2012-present
Member, Committee on Faculty Awards, 9/2011-present
Member, Computerized Provider Order Entry Steering Committee, 1/2010-present
Member, Multiple Myeloma Tissue Bank Steering Committee, 2010-present
Committee Member, Institutional Review Grant (IRG) Committee, 8/2008-7/2011
Committee Member, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Protocol Review Committee, 1/2005-12/2007

Honors and Awards

2006 LLS Man of the Year, Leukemia and Lymphoma Society
2005 LLS Scholar In Clinical Research, Leukemia and Lymphoma Society
2004 Jefferson-Pilot Fellowship, Academic Medicine
2004 Triangle Business Journal Health Care Innovator, Research Award
2003 Young Investigator Award, Clinical Hematology Research
2000 Lymphoma Fellowship Award, Lymphoma Research Foundation of America, Lymphoma Research Foundation of America
1998 Merit Award, American Society of Clinical Oncology, American Society of Clinical Oncology
1983 B.A. in Chemistry from Columbia University Magna Cum Laude, Columbia University
1982 Macy Research Scholarship, Macy
1981 United Hospital Fund Volunteer Service Award, United Hospital Fund
1980-1983 Columbia College Dean's List, Columbia College
1978 Westinghouse Talent Search Honorable Mention, Westinghouse

Selected Publications

Peer-Reviewed Original Research Articles

1. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 5/2015. e-Pub 3/2015. PMID: 25730192.
2. Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J. Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6(11):8567-78, 4/2015. PMID: 25895124.
3. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 4/2015. PMID: 25842049.
4. Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121(7):1138-46, 4/2015. e-Pub 12/2014. PMCID: PMC4368488.
5. Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136(5):991-1002, 3/1/2015. e-Pub 7/23/2014. PMCID: PMC4268424.
6. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang X, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res. e-Pub 3/6/2015. PMID: 25748087.
7. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma 56(3):1-18, 3/2015. e-Pub 8/18/2014. PMCID: PMC4333105.
8. Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res 39(3):371-9, 3/2015. e-Pub 1/3/2015. PMID: 25612941.
9. Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells. Neoplasia 17(3):289-300, 3/2015. PMCID: PMC4372650.
10. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2/2015. e-Pub 7/15/2014. PMCID: PMC4294996.
11. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 29(2):515, 2/2015. PMID: 25651464.
12. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špicka I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma. Am J Hematol 90(1):42-9, 1/2015. e-Pub 10/2014. PMID: 25294016.
13. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 100(1):100-6, 1/2015. e-Pub 9/26/2014. PMCID: PMC4281322.
14. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal Analysis of Patient-Reported Symptoms Post-AuSCT and their Relationship to Inflammation in Patients with Multiple Myeloma. Leuk Lymphoma. e-Pub 11/2014. PMID: 25248883.
15. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
16. Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib-resistance in multiple myeloma through a novel link between autophagy and apoptosis. Blood 124(17):2687-97, 10/2014. e-Pub 9/2014. PMCID: PMC4208284.
17. Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3(5):1275-83, 10/2014. e-Pub 6/2014. PMID: 24913924.
18. Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastritis E, Dimopoulos MA, Shah J. Therapy-Related Myelodysplastic Syndrome/Acute Leukemia After Multiple Myeloma in the Era of Novel Agents. Leuk Lymphoma. e-Pub 10/2014. PMID: 25284489.
19. Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 Induces Cargo-Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. Mol Cell Biol 34(18):3435-49, 9/2014. e-Pub 7/2014. PMCID: PMC4135623.
20. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 8/2014. e-Pub 6/2014. PMID: 24887378.
21. Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ. e-Pub 8/2014. PMID: 25168239.
22. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 7/2014. e-Pub 6/2014. PMID: 24921909.
23. Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu G. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. e-Pub 6/2014. PMID: 24939217.
24. Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20(12):3174-86, 6/2014. e-Pub 4/2014. PMID: 24727327.
25. Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ, Madan A, Avet-Loiseau H, Chopra R. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD® therapy. Leukemia 28(5):1129-31, 5/2014. e-Pub 10/2013. PMCID: PMC4017253.
26. San Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Goh YT, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. e-Pub 5/2014. PMID: 24833354.
27. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123(14):2204-8, 4/2014. e-Pub 1/2014. PMCID: PMC3975258.
28. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 3/2014. e-Pub 1/2014. PMID: 24419515.
29. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. Clin Cancer Res 20(5):1366-74, 3/2014. e-Pub 1/2014. PMCID: PMC3947467.
30. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28(3):525-42, 3/2014. e-Pub 11/2013. PMID: 24253022.
31. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
32. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7(1):127-41, 2/2014. e-Pub 12/2013. PMID: 24350987.
33. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269-77, 2/2014. e-Pub 8/2013. PMID: 23974982.
34. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. J Clin Oncol 32(6):587-600, 2/2014. e-Pub 1/2014. PMCID: PMC3918540.
35. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78-85, 1/2014. e-Pub 10/2013. PMCID: PMC3879908.
36. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5):632-9, 1/2014. e-Pub 12/2013. PMID: 24335104.
37. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma. Leuk Lymphoma 55(1):11-8, 1/2014. e-Pub 6/2013. PMID: 23614765.
38. Zhang L, Morris JS, Zhang J, Orlowski RZ, Baladandayuthapani V. Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics. Cancer Inform 13(Suppl 2):113-23, 2014. e-Pub 12/7/2014. PMCID: PMC4260770.
39. Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. PLoS One 9(3):e89064, 2014. e-Pub 3/2014. PMCID: PMC3942309.
40. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 5/2014. PMCID: PMC4038108.
41. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 9/2014. PMCID: PMC4151993.
42. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB. A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer. Cancer Cell 24(6):791-805, 12/9/2013. PMCID: PMC3881268.
43. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
44. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12):2351-6, 12/2013. e-Pub 5/14/2013. PMCID: PMC3865533.
45. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant 48(12):1537-42, 11/2013. e-Pub 7/15/2013. PMCID: PMC3855173.
46. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122-8, 10/31/2013. e-Pub 9/6/2013. PMCID: PMC3814729.
47. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/ Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 10/2013. e-Pub 7/17/2013. PMID: 23872222.
48. Orlowski RZ. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Semin Oncol 40(5):634-51, 10/2013. PMCID: PMC3819933.
49. Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZ. The Novel Anti-cancer Agent JNJ-26854165 Induces Cell Death Through Inhibition of Cholesterol Transport and Degradation of ABCA1. J Pharmacol Exp Ther 346(3):381-92, 9/2013. e-Pub 7/2/2013. PMID: 23820125.
50. Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. e-Pub 8/2013. PMID: 23988451.
51. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 8/2013. e-Pub 5/2013. PMID: 23733001.
52. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 5/2013. e-Pub 2/2013. PMID: 23432640.
53. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 5/2013. PMID: 23627452.
54. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clin Cancer Res 19(8):2248-56, 4/2013. e-Pub 2/2013. PMID: 23447001.
55. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27(4):780-91, 4/2013. e-Pub 11/2012. PMID: 23288300.
56. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12(6):459-62, 12/2012. e-Pub 9/2012. PMID: 23009979.
57. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 72(24):6393-402, 12/2012. e-Pub 10/2012. PMCID: PMC3525770.
58. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 10/2012. e-Pub 7/2012. PMID: 22833546.
59. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 12(5):310-8, 10/2012. PMID: 23040437.
60. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA. Mol Cancer Ther 11(10):2243-53, 10/2012. e-Pub 8/2012. PMCID: PMC3469746.
61. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 10/2012. e-Pub 8/2012. PMCID: PMC3476538.
62. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
63. Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors up-regulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 72(16):4225-37, 8/2012. e-Pub 6/2012. PMCID: PMC3421040.
64. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: ten years later. Blood 120(5):947-59, 8/2012. e-Pub 5/2012. PMID: 22645181.
65. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Orlowski RZ, and Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158. e-Pub 7/2012. PMID: 22845873.
66. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49(3):258-62, 7/2012. PMID: 22726549.
67. Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiang Y, Gao L, An G, Yang N, Orlowski RZ, Yang L. The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol 44(7):1166-73, 7/2012. e-Pub 4/2012. PMCID: PMC3358443.
68. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. e-Pub 10/2011. PMID: 22015451.
69. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 6/2012. e-Pub 5/2012. PMID: 22555973.
70. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 5/2012. e-Pub 9/2011. PMID: 21887685.
71. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119(16):3668-83, 4/2012. e-Pub 1/2012. PMCID: PMC3335376.
72. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/2012. PMID: 22231283.
73. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥ 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/2011. PMID: 21780997.
74. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119. e-Pub 1/2012. PMID: 22271445.
75. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26(1):149-157, 1/2012. e-Pub 7/2011. PMID: 21799510.
76. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, and Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22. e-Pub 2012. PMID: 22975377.
77. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26. e-Pub 12/2011. PMID: 22193964.
78. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon (CRBN) expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118(18):4771-9, 11/2011. e-Pub 8/2011. PMCID: PMC3208291.
79. Orlowski RZ. The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma. Oncology (Williston Park) 25(12 Suppl 2), 11/2011. PMID: 25188482.
80. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 10/2011. e-Pub 8/2011. PMCID: PMC3204731.
81. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/2011. e-Pub 3/2011. PMID: 21437886.
82. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311-21, 8/2011. e-Pub 6/2011. PMCID: PMC3156932.
83. Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 117(16):3758-62, 8/2011. e-Pub 2/2011. PMID: 21328327.
84. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase (ALP) variation during carfilzomib treatment is associated to best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 6/2011. e-Pub 4/2011. PMID: 21477075.
85. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group. International Myeloma Working Group (IMWG) consensus approach to the treatment of myeloma patients who are candidates for autologous stem-cell transplantation. Blood 117(23):6063-73, 6/2011. e-Pub 3/2011. PMID: 21447828.
86. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus Panel 1. Consensus recommendations for uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 152(18):579-592, 5/2011. e-Pub 2/2011. PMID: 21292775.
87. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(13):11009-20, 4/2011. e-Pub 12/2010. PMCID: PMC3064156.
88. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-592, 3/2011. e-Pub 1/2011. PMID: 21241278.
89. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 3/2011. e-Pub 11/2010. PMID: 21057542.
90. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11(3):285-95, 3/2011. PMID: 21247387.
91. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44-9, 2/2011. PMID: 21454189.
92. Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-158, 1/2011. e-Pub 11/2010. PMID: 21062912.
93. Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 10(6):465-470, 12/2010. PMID: 21147690.
94. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, Orlowski RZ. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89(11):1133-1140, 11/2010. e-Pub 6/2010. PMCID: PMC2940014.
95. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-2452, 10/2010. e-Pub 8/2010. PMCID: PMC2966770.
96. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Droger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127, 2010. PMID: 20410922.
97. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085-7091, 11/2009. e-Pub 11/2009. PMID: 19903785.
98. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147(4):515-525, 11/2009. e-Pub 9/2009. PMID: 19775297.
99. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23(11):1964-1979, 11/2009. e-Pub 9/2009. PMID: 19741722.
100. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10):1716-1730, 10/2009. e-Pub 6/2009. PMID: 19494840.
101. Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you? Blood 113(23):5695-5696, 6/2009. PMID: 19498025.
102. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145(4):481-490, 5/2009. e-Pub 3/2008. PMID: 19344406.
103. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113(19):4667-4676, 5/2009. e-Pub 12/2008. PMID: 19050304.
104. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2/2009. e-Pub 3/2009. PMID: 19436606.
105. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensingeer W, Comenzo RL, Kuman S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, SanMiguel J, Ludwig H. Hajek R, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadora M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV and Durie BG, with the IMWG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904-1912, 2009. PMID: 19494840.
106. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA and Durie BM. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23:1545-1556, 2009. PMID: 19421229.
107. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63(1):99-107, 12/2008. e-Pub 3/2008. PMID: 18327587.
108. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8(6):352-355, 12/2008. PMID: 19064400.
109. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14(17):5416-5425, 9/2008. PMID: 18765533.
110. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112(7):1529-1537, 4/2008. PMID: 18300257.
111. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649-1657, 3/2008. PMID: 18347166.
112. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111(9):4690-4699, 2008. e-Pub 2/2008. PMID: 18305219.
113. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, Hussein MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2). e-Pub 12/2007. PMID: 18094721.
114. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25). e-Pub 8/2007. PMID: 17679727.
115. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17). e-Pub 5/2007. PMID: 17515569.
116. Voorhees PM, Orlowski RZ. Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S156-162, 4/2007. PMID: 17562254.
117. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, and Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 5(10 Suppl 15):7-19, 2007. PMID: 18000495.
118. Voorhees PM, Chen Q, Kuhn DJ, Kuhn DJ, Small GW, Hunsucker, SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 13(21):6469-6478, 2007. PMID: 17975159.
119. Small GW, Shi YY, Higgins LS and Orlowski RZ. Mitogen-activated protein kinasse phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67:4459-4466, 2007. PMID: 17483361.
120. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Su CM, Demo SD, Bennett MK, Van Leeuwen FWB, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110(9):3281-3290, 2007. e-Pub 6/2007. PMID: 17591945.
121. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107(11):2688-2697, 12/2006. PMID: 17075878.
122. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 24(4):234-237, 12/2006. PMID: 16948177.
123. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86(3). e-Pub 12/2006. PMID: 17146676.
124. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100(1):33-47, 11/2006. e-Pub 6/2006. PMID: 16807678.
125. Voorhees PM, Orlowski RZ. Emerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma 7(1):33-41, 7/2006. PMID: 16879768.
126. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19). e-Pub 6/2006. PMID: 16754936.
127. Orlowski RZ, Zeger EL. Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Investig Drugs 15(2):117-130, 2/2006. PMID: 16433592.
128. Ryan DP, O'Neil BH, Supko JG, Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Kusack JC, Jr. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107:2688-2697, 2006. e-Pub 10/2006.
129. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1):51-61, 2006. PMID: 16401713.
130. Orlowski RZ. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program:338-347, 2006. PMID: 17124081.
131. Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2(1):121-135, 2006. PMID: 16556079.
132. Orlowski RZ. The proteasome inhibitor bortezomib. Nat Clin Pract Oncol 3:16-17, 2006. PMID: 16407873.
133. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106(12):3777-3784, 12/2005. e-Pub 8/2005. PMID: 16099887.
134. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105(8):3058-3065, 4/2005. e-Pub 12/2004. PMID: 15626743.
135. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103(6):1195-1200, 3/2005. PMID: 15690325.
136. Ramaswamy B, Povoski S, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendear K, Somasundaram S, Orlowski RZ, Shapiro CL. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 93(1):67-74, 2005. PMID: 16184461.
137. Orlowski RZ. The ubiquitin-proteasome pathway from bench to bedside. Hematology 2005:220-225, 2005. PMID: 16304384.
138. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66(6):1478-1490, 12/2004. e-Pub 9/2004. PMID: 15448190.
139. Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma 45(11):2215-2219, 11/2004. PMID: 15512809.
140. Orlowski RZ. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 4(2):171-179, 4/2004. PMID: 15056047.
141. Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 45(1):187-188, 2004. PMID: 15061219.
142. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42 MAPK. J Pharmacol Exp Ther 307(3):861-869, 12/2003. e-Pub 10/2003. PMID: 14557375.
143. Richardson PG, Barlogie B, Berenseon J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanina R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Esseltine D-L, Kauffman M, Schenkein DP and Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 6/2003. e-Pub 10/2003. PMID: 12826635.
144. Orlowski RZ, Dees EC. Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5(1):1-7, 2003. e-Pub 8/2002. PMID: 12559038.
145. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 9(17):6316-6325, 2003. PMID: 14695130.
146. van Deventer HW, Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, Shea TC. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Am J Hematol 71(3):184-190, 11/2002. PMID: 12410573.
147. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420-4427, 11/2002. PMID: 12431963.
148. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277(31):27864-27871, 8/2002. e-Pub 5/2002. PMID: 12023956.
149. Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8(8):385-389, 8/2002. PMID: 12127724.
150. Small GW, Chou TY, Dang CV, Orlowski RZ. Evidence for involvement of calpain in c-Myc proteolysis in vivo. Arch Biochem Biophys 400(2):151-161, 4/2002. PMID: 12054425.
151. Somasundaram S, Edmund, NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62(13):3868-3875, 2002. PMID: 12097302.
152. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60(21):6178-6183, 11/2000. PMID: 11085542.
153. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6(4):303-313, 4/1999. PMID: 10381632.
154. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58(19):4342-4348, 10/1998. PMID: 9766662.
155. Orlowski R. Epstein-Barr Virus Nuclear Antigen Number One: Cloning, Purification and Aspects of Function. Ph.D. Dissertation, 1991.
156. Orlowski R, Miller G. Single stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication. J Virol 65:677-686, 1991. PMID: 1846191.
157. Orlowski R, Polvino-Bodnar M, Hearing J, and Miller G. Inhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies. Virology 176:638-642, 1990. PMID: 2161154.
158. Orlowski R, Miller G. Topological effects of EBNA 1 on ori P. Advances in Experimental Medicine and Biology: Immunobiology and Prophylaxis of Human Herpesvirus Infections 278:115-124, 1990. PMID: 1963028.
159. Orlowski M, Orlowski R, Chang JC, Wilk E, Lesser M. A sensitive procedure for determination of cathepsin D: Activity in alveolar and peritoneal macrophages. Mol Cell Biochem 64(2):155-162, 9/1984. PMID: 6150434.

Abstracts

1. Siegel DSD, Moreau P, Avigan D, Anderson KC, Reece DE, San Miguel J, Mateos M-V, Wu D, Emancipator K, Dolled-Filhart M, Gause C, Brown H, Heath K, Iannone R, Rose S, Orlowski RZ. A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 32(5s) (#TPS3117), 2014.
2. Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). J Clin Oncol 32 (#e20669), 2014.
3. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. J Clin Oncol 32(5s) (#8601), 2014.
4. Popat UR, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah JJ, Orlowski RZ, Qazilbash MH, Bashir Q and Champlin RE. Clinical Autologous Transplantation: Results: Clinical Results in Plasma Cell Dyscrasias 2. Blood 731, 2014.
5. Mian I, Popat UR, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah JJ, Orlowski RZ, Qazilbash MH, Bashir Q and Champlin RE. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. Blood 731(194), 2014.
6. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A. Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood 653(3448), 2014.
7. Henderson MD, Kolonel LN, Anderson KC, Chiu B C-H, Zonder J, Orlowski RZ, Lonial S, Stram DO, Haiman C, Cozen W. Genetic Susceptibility Markers of Multiple Myeloma in African-Americans. Blood 651(2030), 2014.
8. Wang Hua, Gu D, Zhong L, Ma W, Davis RE, and Orlowski RZ. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Alternative Targets and Mechanism of Drug Resistance in Lymphomas and Myelomas. Blood 605, 2014.
9. Wang H, Wang HUA, Gu D, Zhong L, Ma W, Davis RE, and Orlowski RZ. Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma. Blood 605(274), 2014.
10. Yang J, Liu Z, Liu H, He J, Lin P, Orlowski RZ, Kwak LW, Tong Q, and Gagel R. Myeloma Cells Switch Osteoblastogenesis to Adipogenesis and Suppress Bone Formation. Blood 651(3386), 2014.
11. Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, and Orlowski RZ,. Myeloma: Therapy, excluding Transplantation I. Blood 653, 2014.
12. Vogl D, Hari, MR, Jones SS, Supko JG, Leone G, Wheeler C, Orlowski RZ, Richardson PG, Lonial S, Tamang D, and Jagannath S. Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). Blood 653(4764), 2014.
13. Thomas SK, Melendez AG, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). J Clin Oncol 32(5s) (#8536), 2014.
14. Shah JJ, Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, and Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 653(33), 2014.
15. Shah N, Popat R, Hosing CM, Patel KK, Lin P, Shpall EJ, Orlowski RZ, Champlin RE and Qazilbash MH,. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. Blood 731(3981), 2014.
16. Shi Q, Wang XS, Shah N, Orlowski RZ, Qazilbash MH, Williams LA, Mendoza TR, Cleeland CS. Prevalence of high symptom burden and its impact on functioning and quality of life in patients with multiple myeloma 3-9 months following autologous transplant. J Clin Oncol 32 (#e19580), 2014.
17. Qazilbash MH, Thall PF, Fox PS, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Valdez B, Parmar S, Dinh Y, Hosing C, Popat UR, Shah JJ, Orlowski RZ, Champlin RE. Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. J Clin Oncol 32(5s) (#8538), 2014.
18. Zhang Z-D, Yang J, Davis RE, Ma W, Wang Z, Yang L, Orlowski RZ,. Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity. Blood 651(3414), 2014.
19. Usmani SZ, Hoering A, Sexton R, Ailawadhi S, Shah JJ, Fredette S, Durie BG, Zonder JA, Dhodapkar MV, Rajkumar SV, Mahindra AK, Zimmerman TM, Richardson PG, Orlowski RZ. SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). J Clin Oncol 32(5s) (#TPS8624), 2014.
20. Usmani S, Fredette S, Durie B, Hoering A, Rajkumar SV, Richardson PG and Orlowski RZ. SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM). Blood 653(4762), 2014.
21. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T. Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood Oral Presentation 653, 2014.
22. Tunquist B, Brown K, Hingorani G, Aitchison R, Regensburger J, Lonial S, Kaufman J, Zonder J, Cohen A, Bensinger W, Orlowski R, Shah J, Hilder B, Ptaszynski M, Litwiler K, Walker D. Alpha 1-Acid Glycoprotein (AAG) is a Potential Patient Selection Biomarker for Improved Clinincal Activity of ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). Submitted to EHA 2013, 2013.
23. Wheeler C, Raje N, Mahindra A, Vogl D, Voorhees P, Bensinger W, Hari P, Berdeja J, Jagannath S, Jones S, Supko J, Orlowski RZ, Lonial S. New Drug Partner for Combination Therapy in Multiple Myeloma (MM): Development of Acy-1215, A Selective Histone Deacetylase 6 inhibitor alone and in combination with Bortezomib (B) or Lemalidomide (L). Submitted to EHA 2013, 2013.
24. Orlowski RZ. Phase II, randomized, double blind, placebo-controlled study with comparing siltuximab plus bortezomib versus bortezomib alone in patients with relapsed/refractory multiple myeloma. ASCO, 2013.
25. San Miguel J, Blade J, Shpilbert O, Grosicki S, Maloisel F, Min C-K Mediavilla JD, robak T, Khuageva N, Prasad SV, Goh YT, Laubach J, Spencer A, Mateos M-V, Palumbo A, van de Velde H, Uhlar C, Qin X, Xie H, Orlowski R. Randomized, Open-Label, Phase 2 Study of Siltuximab (an Anti -L 6 MAB) and Bortezomib-Melphalan-Prednisone versus Bortezomib-Melphalan-Prednisone in Patients with Previously Untreated Multiple Myeloma. EHA, 2013.
26. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Orlowski RZ, Kim EL, McKinley MB, and Durie BGM. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(74), 2012.
27. Glitza IC, Lu G, Chen S, Orlowski RZ, and Qazilbash MH. C-MYC Rearrangement: A Marker for High-Risk Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4989), 2012.
28. Shah JJ, Hegde A, Zhou X, Thomas SK, Wang M, Weber DM, Alexanian R, Orlowski RZ, and Vadhan-Raj S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (ASH Annual Meeting Abstracts) 120(2244), 2012.
29. Cozen W, Hwang AE, Ailawadhi S, Singhal S, Huff CA, Bernal-Mizrachi L, Chiu BC-H, Brown EE, Peters E, Pawlish K, Mohrbacher A, Bock CH, Haiman C, Stram DO, Rand KA, Tomasson MH, Jain N, Van Den Berg DJ, Graff JJ, Colditz GA, Zimmerman TM, Zonder J, Orlowski RZ, and Lonial S. Explaining the Excess Risk of Multiple Myeloma in African-Americans. Blood (ASH Annual Meeting Abstracts) 120(4002), 2012.
30. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Kunkel L, Rajangam K, Chang Y-L, Wear S, Orlowski RZ, Stewart AK. Exploratory analysis of treatment-refractory subgroups from the single-agent carfilzomib trial PX-171-003-A1 in patients with relapsed and refractory multiple myeloma. Lymphoma & Myeloma 2012 Conference in New York, 2012.
31. Shah JJ, Orlowski RZ, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Popat UR, Parmar S, Shah N, Bashir Q, Champlin RE, and Weber DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood (ASH Annual Meeting Abstracts) 120(75), 2012.
32. Parmar S, Howell J, Wang M, Khan MA, Bashir Q, Shah JJ, Shah N, Popat UR, Giralt SA, Orlowski RZ, and Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood (ASH Annual Meeting Abstracts) 120(750), 2012.
33. Tunquist B, Brown K, Hingorani G, Lonial S, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Orlowski RZ, Shah JJ, Hilder B, Ptaszynski AM, Koch K, Litwiler K, and Walker D. Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts) 120(1868), 2012.
34. Weiss M, Jacobus S, Abonour R, Anderson KC, Barlogie B, Callander N, Gorak EJ, Hoering A, Kane RC, Katz MS, Matous J, Mills GM, Omel J, Orlowski RZ, Rajkumar SV, Richardson PG, Jensen LA, Little RF, Gertz MA, and Munshi NC. Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials. Blood (ASH Annual Meeting Abstracts) 120(3165), 2012.
35. Zhang X-D, Orlowski RZ, and Yang L. Identification of Tight Junction Protein (TJP)-1 As a Modulator of Sensitivity to Doxorubicin and Cisplatin in Models of Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(3962), 2012.
36. Thomas SK, Delasalle KB, Shah JJ, Wang L, Orlowski RZ, and Weber DM. Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts) 120(2734), 2012.
37. Kuiatse I, Thomas SK, Weber DM, Stein AM, Wang M, Shah JJ, Treon SP, Ansell SM, and Orlowski RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120(3723), 2012.
38. Gu D, Jones RJ, Wang H, Leopold L, and Orlowski RZ. Inhibition of the HDM-2 E3 Ligase Induces Types I and II Cell Death in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically in Both with ABT-737. Blood (ASH Annual Meeting Abstracts) 120(2940), 2012.
39. Fowler NH, Neelapu SS, Hagemeister Fb, McLaughlin P, Kwak LK, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, and Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstracts) 120(901), 2012.
40. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C, Harvey RD, Gleason C, Casbourne D, Nooka AK, Heffner LT, Richardson PG, Orlowski RZ, and Lonial S. Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. Blood (ASH Annual Meeting Abstracts) 120(336), 2012.
41. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, and Yang J. P38 MAPK Activity in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction in Vivo. Blood (ASH Annual Meeting Abstracts) 120(566), 2012.
42. Siegel DS, Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Kunkel L, Rajangam K, Chang Y-L, Orlowski RZ, Stewart AK and the MMRC. Patients refractory or intolerant to both bortezomib and immunomodulators show similar overall response rates to other clinically relevant subgroups in the single agent carfilzomib trial PX-171-003-A1. ASCO 2012, 2012.
43. Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, and Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4082), 2012.
44. Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian A, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, and Orlowski RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4081), 2012.
45. Orlowski R, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos M-A, Cavenagh J, Spicka I, Maiolino A, Komarnicki M, Suvorov A, Blade J, Samoilova O, van de Velde H, Bandekar R, Kranenberg B, Xie H, Rossi J-F. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Comparing Siltuximab + Bortezomib vs. Bortezomib Alone in Pts with Relapsed/Refractory Multiple Myeloma. J Clin Oncol, 2012.
46. Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi VV, and Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(2976), 2012.
47. Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Rajangam K, Wear S, Orlowski RZ, and Siegel DS. PX-171-003-A1, an Open-label, Single-arm Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma: Long-term Follow-up and Subgroup Analysis. ISH, 2012.
48. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale <, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, and Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(3707), 2012.
49. Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG, Stephenson P, Jones SS, Wheeler C, and Lonial S. Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 120(4061), 2012.
50. Patel K, Orlowski RZ, Shah N, Bashir Q, Parmar S, Dinh YT, Rondon G, Giralt SA, Champlin RE, and Qazilbash M. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(3115), 2012.
51. Shah JJ, Zonder JA, Cohen A, Bensinger W, Kaufman JL, Orlowski RZ, Harvey RD, Abidi MH, Thomas SK, Walker D, Hilder B, Ptaszynski AM, and Lonial S. The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 120(449), 2012.
52. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, and Qazilbash MH. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 118. e-Pub 11/2011.
53. Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, De Lima M, Champlin R, and Giralt S. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood 118. e-Pub 11/2011.
54. Shah JJ, Zonder J, Cohen A, Orlowski RZ, Alexanian R, Thomas SK, Weber D, Kaufman JL, Harvey RD, Walker D, Litwiler K, Karan S, Hilder B, Ptaszynski AM, and Lonial S. ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. Blood 118. e-Pub 11/2011.
55. Kuhn DJ, Wang H, Jones FJ, Bjorklund CC, and Orlowski RZ. Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma. Blood 118. e-Pub 11/2011.
56. Zhu YX, Braggio E, Shi C-X, Schmidt J, Bruins L, Schuster SR, Fonseca R, Bergsagel PL, Bjorklund CC, Orlowski RZ, and Stewart AK. Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide. Blood 118. e-Pub 11/2011.
57. Glitza IC, Lu G, Chen Su, Orlowski RZ, and Qazilbash M. Clinical Features of Patients with Multiple Myeloma and C-MYC Rearrangements. Blood 118. e-Pub 11/2011.
58. Wang XS, Shi Q, Cleeland CS, Mendoza TR, Williams L, Joy J, Ilagan VM, Mobley GM, Gilmore KR, and Orlowski RZ. Development of Patient-Reported Bortezomib-Induced Peripheral Neuropathyin Multiple Myeloma Patients Undergoing Induction Therapy. Blood 118. e-Pub 11/2011.
59. Kumar S, Lee JH, Lahuerta JJ, Morgan GJ, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hullin C, Klein SK, Sonneveld P, Siegel DS, Bladé J, Goldschmidt H, Jagannath S, San Miguel JF, Orlowski RZ, Palumbo A, Sezer O, Rajkumar SV, and Durie BGM. Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. Blood 118. e-Pub 11/2011.
60. Jones RJ and Orlowski RZ. Drug Resistance to the HDM-2 Inhibitors MI-63 and Nutlin Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA. Blood 118. e-Pub 11/2011.
61. Patel K, Orlowski RZ, Shah N, Bashir Q, Dinh YT, Rondon G, Giralt S, Champlin R, and Qazilbash MH. Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome. Blood 118. e-Pub 11/2011.
62. Vij R, Kaufman JL, Jakubowiak AJ, Wang M, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch AR, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Wear S, Kunkel L, Wong AF, Lee P, and Stewart K. Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood 118. e-Pub 11/2011.
63. Ahmed S, Lin H, Baladandayuthapani V, Khan MA, Lu G, Rondon G, Qureshi S, Dinh YT, Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Champlin R, and Qazilbash MH. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118. e-Pub 11/2011.
64. Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, and Jagannath S. Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood 118. e-Pub 11/2011.
65. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Mattar BI, Safah HF, Holmberg L, Dean RM, Orlowski RZ, and Barlogie B. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. Blood 118. e-Pub 11/2011.
66. Munker R, Setoyama T, Duvic M, Orlowski RZ, and Calin G. Regulation of Selected MicroRNAs in Multiple Myeloma. Blood 118. e-Pub 11/2011.
67. San Miguel JF, Richardson PG, Orlowski RZ, Goldschmidt H, Corzo D, Satler C , Esseltine D-L, Neuwirth R, Ponsillo M, Cakana AZ, King J, Deraedt WM, Desai A, Lutska Y, Gifkins D, Liu K, and Sonneveld P. Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). Blood 118. e-Pub 11/2011.
68. Ahmed S, Dinh YT, Qureshi S, Rondon G, Bashir Q, Parmar S, Avery T, Orlowski RZ, Champlin R, Qazilbash M, and Shah N. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. Blood 118. e-Pub 11/2011.
69. Bjorklund CC, Aukerman SL, Lopez-Girona A, Hussein M, Chopra R, Kuiatse I, Kuhn DJ, Wei C, and Orlowski RZ. Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma. Blood. e-Pub 11/2011.
70. Lonial S, Cohen A, Zonder J, Benzinger WI, Kaufman JL, Orlowski RZ, Harvey RD, Alexanian R, Thomas SK, Weber D, Walker D, Hilder B, Ptaszynski A, and Shah JJ. The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood 118. e-Pub 11/2011.
71. Jakubowiak AJ, Siegel DS, Singhal S, Martin T, Lonial S, Kukreti V, Bahlis N, Chanan-Khan AA, Alsina M, Somlo G, Buadi FK, Reu FJ, Song KW, Kunkel L, Wear SM, Wong AF, Orlowski RZ, Stewart AK, Jagannath S, and Wang L. Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood 118. e-Pub 11/2011.
72. Yang L, Zhang X, Wang H, Orlowski RZ, and Huang X. Validation of Potential Chemosensitivity Genes in Multiple Myeloma. Blood 118. e-Pub 11/2011.
73. Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, and Hurd DD. Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study. Blood 118. e-Pub 11/2011.
74. Kuhn DJ, Bjorklund CC, Wang M, Huo Y, and Orlowski RZ. Bortezomib resistance is mediated by increased signaling through cancer Osaka thyroid (Cot) kinase. 2011 International Myeloma Workshop, 2011.
75. Wang M, Stewart AK, Kaufman JL, Jakubowiak AJ, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Kunkel LA, Le MH, Lee P, Rosen P, Sebag M, Vij M, and The Multiple Myeloma Research Consortium (MMRC). Carfilzomib (CFZ) produces a high single agent response rate with minimal neuropathy even in relapsed multiple myeloma (MM) patients (pts) with high-risk disease. 2011 International Myeloma Workshop, 2011.
76. Zhu YX, Braggio E, Shi C-X, Schmidt JE, Bruins LA, Fonseca R, Bergsagel PL, Kuhn D, Orlowski R, and Stewart AK. Cereblon (CRBN) is a requirement for the anti-myeloma activity of thalidomide, lenalidomide and pomalidomide. 2011 International Myeloma Workshop, 2011.
77. Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski RZ, Shah J, Alexanian A, Thomas S, Qazilbash M, Badilo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen, L. Electroacupuncture is an effective therapeutic modality for bortezomib- or thalidomide-induced peripheral neuropathy in patients with multiple myeloma and mantle cell lymphoma: A pilot study. 2011 International Myeloma Workshop, 2011.
78. Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Lacerte L, Fowler NH. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 29 (#8030). e-Pub 2011.
79. Dimopoulos MA, Orlowski RZ, Niesvizky R, Lonial S, Brandenburg NA, Weber DM. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. J Clin Oncol 29 (#8009). e-Pub 2011.
80. Durie BG, Morgan G, San-Miguel JF, Orlowski RZ, Lonial S, Niesvizky R, Yu Z, Anderson KC. Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. J Clin Oncol 29 (#8086). e-Pub 2011.
81. Yong K, Orlowski R, Cavet J, Cole C, Davies F, Wlliams C, Akinaga S, Francis G, Rao N, Cavenagh J. Phase 1/2 trial of KW-2478 plus bortezomib in patients with relapsed/refractory multiple myeloma: results from the phase 1 portion. 2011 International Myeloma Workshop, 2011.
82. Orlowski RZ, Wang XS, Mendoza TR, Williams LA, Johnson VE, Joy J, Ilagan V, Mobley GM, Liu P, Gilmore KR, Cleeland CS. Prevalence and trajectory of disease- and treatment-related symptom burden in patients with multiple myeloma undergoing induction therapy. J Clin Oncol 29 (#e19627). e-Pub 2011.
83. Siegel DSD, Martin T, Wang M, Vij R, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Somlo G, Buadi F, Reu FJ, Song KW, Kunkel LA, Wong A, Vallone M, Orlowski RZ, Stewart AK, Singhal S, Jagannath S, Jakubowiak AJ. PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. J Clin Oncol 29 (#8027). e-Pub 2011.
84. Martin T, Siegel DS, Wang M, Vij R, Lonial S, Kukreti V, Bahlis N, Alsina M, Somlo G, Buadi F, Reu F, Song K, Kunkel L, Wong A, Vallone M, Orlowski R, Stewart AK, Singhal S, Jakubowiak AJ, the Multiple Myeloma Research Consortium (MMRC), Jagannath J. Results of PX-171-003-A1, an open-label, single-arm, phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM). 2011 International Myeloma Workshop, 2011.
85. Morgan G, Durie B, San Miguel J, Orlowski R, Lonial S, Palumbo(6) Niesvizky AR, Baz R, Giralt S, Bensinger W, Brandenburg NN, Yu Z, Boccadoro M, Richardson P, Anderson K,. Retrospective analysis of the long term safety of lenalidomide (LEN) +/- dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM). 2011 International Myeloma Workshop, 2011.
86. Richardson P, Orlowski R, San Miguel J, Niesvizky R, Attal M, Baz R, Brandenburg N, Lonial S, Bensinger W. Risk of second primary malignancies (SPM) in relapsed/refractory multiple myeloma (RRMM) patients (pts) treated with lenalidomide and dexamethasone (LEN+DEX): analysis of MM-009/010 SPM incidence rate (IR). 2011 International Myeloma Workshop, 2011.
87. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, and Weber D. The regimen of lenalidomide (len), thalidomide (thal), and dexamethasone (dex) is active against relapsed and/or refractory multiple myeloma (RRMM) and overcomes lenalidomide resistance. 2011 International Myeloma Workshop, 2011.
88. Shah JJ, Zonder JA, Cohen A, Weber D, Thomas S, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Rush SA, Ptaszynski A, Orlowski RZ and Lonial S. A phase I/II trial of the KSP inhibitor ARRY-520 in relapsed/refractory multiple myeloma. Blood 116 (#1959), 2010.
89. Martin T, Singhal SB, Vij R, Wang M, Stewart AK, Jagannath S, Lonial S, Jakubowiak AJ, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer EA, Wong AF, Vallone M, Chang Y-L, Kauffman M, Orlowski RZ and Siegel DS diC. Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): Results of a subset analysis of a phase 2 trial in patients with relapsed and refractory multiple myeloma (RRMM). Blood 116 (#3031), 2010.
90. Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DJ, Orlowski RZ, le MH, Lee P, Wang M, and the MMRC. Carfilzomib: High single agent response rate with minimal neuropathy even in high-risk patients. Blood 116 (#1938), 2010.
91. Bensinger W, Wang M, Orlowski RZ, Alsina M, Martin T, Singhal S, Gabrail Y, Vallone M, Kauffman M and Niesvizky R. Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). American Society of Clinical Oncology 45th Annual Meeting (#8029), 2010.
92. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE and Qazilbash MJ. High dose melphalan with autologous stem cell transplantation overcomes poor prognosis of primary amyloidosis. Blood 116 (#1350), 2010.
93. Kaufman JL, Shah JJ, Laubach JP, Heffner L, Francis D, Harvey RD, Lewis C, Tighiouart M, Richardson P, Orlowski RZ and Lonial S. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Initial results of a phase 1 study. Blood 116 (#3034), 2010.
94. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Patterson M, Harvey D, Berger AJ, McDonald A, Mulligan G, Boral A, Pickard MD, Smith PG, Kuan HS, Walker R, Garnsey J, Burke K, Lonial S. MLN4924, a novel investigational NEDD8-activating enzyme (NAE) inhibitor, in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL): Phase 1 dose-escalation study. 15th Congress of EHA, 2010.
95. Reed VK, Shah JJ, Mazloom A, Weber DM, Phan J, Orlowski RZ, Thomas SK, Wang M, Alexanian R, Dabaja BS. Outcome and prognostic factors in solitary plasmacytoma. American Society of Clinical Oncology 45th Annual Meeting 28(15):May 20 supplement (#e18512), 2010.
96. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE and Qazilbash MH. Outcome of high dose melphalan with autologous hematopoietic stem cell transplant in myeloma associated with AL amyloidosis. Blood 116 (#2400), 2010.
97. Shah JJ, Harvey DR, O'Connor OA, Jakubowiak AJ, Smith MR, Orlowski RZ, Mulligan GJ, Smith PG, Pickard MD, Dezube BJ and Lonial S. Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma. Blood 116 (#2801), 2010.
98. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U and Weber D. Phase I trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood 116 (#1948), 2010.
99. Singhal SB, Siegel DS diC, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Kauffman M, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK and Jagannath S. Pooled safety analysis from phase (Ph) 1 and 2 studies of carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (MM). Blood 116 (#1954), 2010.
100. Jakubowiak AJ, Martin T, Singhal SB, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Bray L, Vallone M, Kauffman M, Orlowski RZ, siegel DS diC and The MMRC. Responses and survival are not affected by cytogenetics in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent carfilzomib. Blood (#1942), 2010.
101. Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore M, Strader J, Orlowski RZ and Hurd DD. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. Blood 116 (#1955), 2010.
102. Siegel SD diC, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer E, Wong AF, Vallone M, Chang Y-L, Kauffman M, Orlowski RZ, Stewart AK, Singhal SB and the MMCR. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood 116 (#985), 2010.
103. Bjorklund CC, Kuhn DJ, Matthews JA, Wang M, Baladandayuthapani V, Orlowski RZ. Activation of the Wnt/β-Catenin pathway mediates lenalidomide resistance in multiple myeloma. Blood 114(113), 2009.
104. Zangari M, Polavaram L, Zhan F, Tricot GJ, Ravi V, Jagannath S, Siegel D, Stewart AK, Wang, L, Orlowski RZ, Belch A, Jakubowiak AJ, Somlo G, Trudel S, Bahlis NJ, Lonial S, Singhal S, Kukreti V. Alkaline phosphatase (ALP) variation during carfilzomib treatment is associated to best response in multiple myeloma. Blood 114(2865), 2009.
105. Kuhn DJ, Bjorklund CC, Magarotto V, Matthews JA, Wang M, Balandandayuthapani V, Orlowski RZ. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1/Akt axis. Blood 114(2739), 2009.
106. Vij R, Wang L, Orlowski RZ, Stewart AK, Jagannath S, Lonial S, Trudel S, Jakubowiak AJ, Belch A, Alsina M, Bahlis NJ, Le MH, Cruickshank S, Bennett MK, Molineaux S, Kauffman M, Siegel D, The Multiple Myeloma Research Consortium (MMRC). Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood 114(430), 2009.
107. Delasalle KB, Wang L, Weber D, Giralt SA, Thomas S, Shah J, Handy B, Orlowski RZ, Alexanian R. Curability of multiple myeloma. Blood 114(3864), 2009.
108. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable remission with salvage autotransplants in patients with multiple myeloma. Blood 114(1227), 2009.
109. Magarotto V, Londhe A, Lantz KC, Lowery C, Sonneveld P, Blade J, Harousseau J-L, Orlowski RZ. Impact of Baseline Free Light Chair Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal DOxorubicin Plus bortezomib or Bortezomib Alone. Blood 114(4778), 2009.
110. Jakubowiak A., Wang L, Orlowski RZ, Jagannath S, Siegel D, Stewart AK, Kukreti, V, Lonial S, McDonagh DT, Vallone M, Kauffman M, Vij R, The Multiple Myeloma Research Consortium (MMRC). Influence of cytogenetics in patients with relapsed and refractory multiple myeloma (MM) treated with carfilzomib (CFZ). Blood 114(1827), 2009.
111. Hunsucker SA, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 sensitizes plasma cell dyscrasias to the effects of melphalan in association with suppression of signaling through protein kinase B/Akt. Blood 114(1836), 2009.
112. Trudel S, Lee S, Kirk CJ, Gabrail N, Lonial S, Wang L, Orlowski RZ, Kukreti V, Stewart AK, Jagannath S, McDonagh KT, Buadi F, Zonder JA, Bennett MK, The Multiple Myeloma Research Consortium (MMRC). Inhibition of the proteasome in bone marrow-derived CD 138+ tumor cells following carfilzomib administration in relapsed or refractory myeloma patients. Blood 114(1845), 2009.
113. Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, Laubach J, Moreau P, Morgan G, Orlowski, RZ, Palumbo A, Richardson P, San Miguel JF, Sezer O, Siegel D, Sonneveld P, Szymonifka J, Rajkumar SV, Durie BGM. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Blood 114(2878), 2009.
114. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Patterson M, Harvey D, Berger AJ, McDonald A, Mulligan G, Petruzzelli L, Pickard MD, Smith PG, Venkatakrishnan K, Lonial S. Phase 1 dose-escalating study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. Blood 114(1854), 2009.
115. Niesvizky R, Wang L, Orlowski RZ, Bensinger W, Alsina M, Gabrail N, Gutierrez A, Kunkel L, Kauffman M, The Multiple Myeloma Research Consortium (MMRC). Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 114(304), 2009.
116. Thomas SK, Feng L, Delasalle KB, Wang M, Shah JJ, Orlowski RZ, Alexanian R, Weber DM. Prognostic factors for survival after 2-CdA-based therapy for symptomatic Waldenström macroglobulinemia (M) stratify patients into low- and high-risk groups. Blood 114(1668), 2009.
117. Vij R, Wang M, Orlowski RZ, Stewart AK, Jagannath S, Kukreti V, Le MH, Kunkel L, Siegel D. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. Am Soc Clin Oncol 45 Annual Meeting, 2009.
118. Siegel D, Wang L, Orlowski RZ, Kaufmann JL, Stewart AK, Kukreti V, Alsina M, Jakubowiak, AJ, Jagannath S, McDonagh KT, Belch A, Bahlis NJ, Shustik C, Le MH, Kunkel L, Bennett MK, Kauffman M, Vij R, The Multiple Myeloma Research Consortium (MMRC). PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood 114(303), 2009.
119. Shah N, Weber D, Orlowski R, Wang M, Thomas SK, Richards T, Giralt S, Qazilbash M, Alexanian R, Shah JJ. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. Am Soc Clin Oncol 45th Annual Meeting(8596), 2009.
120. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival disparities between African-American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Blood 114(1395), 2009.
121. Dai Y, Chen S, Pei X-Y, Ramakrishnan V, Wang M, Orlowski R, Dent P, Grant S. Targeting CDK9 dramatically potentiates ABT-737-induced apoptosis in human multiple myeloma cells through a Bim-dependent mechanism. Blood 114(297), 2009.
122. Wang L, Siegel D, Kaufman JL, Stewart AK, Jakubowiak AJ, Alsina M, Kukreti V, Bahlis NJ, McDonagh KT, Belch A, Sebag M, Gabrial N, Le MH, Bennett MK, Kunkel L, Kauffman M, Orlowski RZ, Vij R, The Multiple Myeloma Research Consortium (MMRC). Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood 114(302), 2009.
123. Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Dodd A, Foster MC, Gabriel DA, Shea TC, Serody J, van Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study. Blood 114(306), 2009.
124. Spencer A, Hajek R, Nagler A, Sonneveld P, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® and VELCADE® in previously treated high risk myeloma. Int'l Soc. Onc. Pharmacy Practitioners XI/Hematology/Oncology Pharmacy Association 2008 Joint Annual symposium, 6/2008.
125. San Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Blade J, robak T, Mndle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® and VELCADE® in previously treated myeloma patients aged ≥65 years. Intl Soc Oncol Pharmacy Practitioners XI/Hematology/Oncology Pharmacty Association 2008 Joint Annual Symposium, 6/2008.
126. Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, Hennessey K, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Int'l Soc Onc Pharmacy Practitioners XI/Hematology/Oncology Pharmacy Association 2008 Joint Annual Symposium, 6/2008.
127. O'Connor OA, Goy A, Orlowski R, Hainsworth JD, Leonard JP, Afanasyev B, Osmanov D, Chen M, Wolff A. A Phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. J Clin. Oncol. 26(8539):463s, 2008.
128. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, Giralt SA. A randomized phase II trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma. Blood 112(3320), 2008.
129. Jones RJ, Arts J, Orlowski RZ. Inhibition of the human double minute (HDM)-2 E3 ubiquitin ligase activates different programmed cell death (PCD) pathways in models of non-Hodgkin lymphoma (NHL) with wild type (wt) and mutant (mut) p53. Blood 112(3618), 2008.
130. Vij R, Wang M, Orlowski RZ, Stewart AK, Jagannath S, Kukreti V, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D, and The Multiple Myeloma Research Consortium (MMRC). Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood 112(865), 2008.
131. Voorhees PM, Manges R, Sonneveld P, Somlo G, Jagannath S, Zweegman S, Munteanu M, Vermeulen JT, Xie H, Orlowski RZ. Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). J. Clin. Oncol.(4903):301b, 2008.
132. Rossi J-F, Manges RF, Sutherland HJ, Jagannath S, Voorhes P, Sonneveld P, Delforge M, Pegourie B, Alegre A, de la Rubia J, La Police D, Bandekar R, Xie H, Orlowski RZ. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 112(867), 2008.
133. Cole, SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MJ. Reduced-intensity regimens for allogeneic stem cell transplantation improve the outcome in advanced multiple myeloma. Blood 112(3298), 2008.
134. Blade J, Sonneveld P, San Miguel J, Sutherland H, Hajek R, Nagler A, Spencer A, Robak T, Harousseau JL, Orlowski RZ. The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal impairment. J Clin Oncol 26(8562):469s, 2008.
135. Yang L, Orlowski RZ. ZKSCAN3, a novel zinc finger transcription factor, regulates Cyclin D2 expression in multiple myeloma (MM) cells. Blood 112(749), 2008.
136. O'Connor O, Goy A, Orlowski RZ, Hainsworth J, Leonard J, Afanasyev B, Osmanov D, Reyno LM, Chen MM, Escandon R. A phase I-II study to determine the safety, pharmacokinetics and potential efficacy of intravenous administration of SB-743921 on days 1 and 15 of 28 day dosing schedule in patients with non-Hodgkin's lymphoma. Blood 110(2556):753a, 2007.
137. Chen Q, Esseltine D-L, Neuwirth RB, Richardson PG, Orlowski RZ. Ciprofloxacin inhibits bortezomib-mediated apoptosis in multiple myeloma models in association with induction of heme oxygenase-1. Blood 110(2365):698a, 2007.
138. Alsina M, O'Connor OA, Stewart AK, Trudel S, Urquilla PR, Vallone MK, Molineaux CJ, Goy A, Orlowski RZ. Clinical responses in multiple myeloma and Waldenström's macroglobulinemia with the proteasome inhibitor carfilzomib (PR-171). Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (S2)(611):156, 2007.
139. Spencer A, Hajek R, Nagler A, Sonneveld P, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated high risk myeloma. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (s2)(629):162, 2007.
140. San Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated myeloma patients aged ≥65 years. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece 92 (s2)(620):159, 2007.
141. Nagler A, Hajek R, Sonneveld P, Spencer A, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated myeloma patients with prior stem cell transplant. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (s2)(625):161, 2007.
142. Orlowski RZ, Sutherland HJ, Blade J, San-Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Robak T, Mundle SD, Luo D, Zhuang SH, Harousseau JL. Early normalization of serum free light chain is associated with prolonged time to progression following bortezomib ± pegylated liposomal doxorubicin treatment of relapsed/refractory multiple myeloma. Blood 110(2735):803a, 2007.
143. Sutherland HJ, Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, O'Neal W, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. Effect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin + bortezomib vs. bortezomib alone in relapsed/refractory multiple myeloma. Blood 110(2740):805a, 2007.
144. Harousseau J-L, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, Robak T, Xiu L, Zhuang SH, Orlowski RZ, for the DOXIL-MMY-3001 study investigators. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol 25(8002):441s, 2007.
145. Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, Zhunang SH, Harousseau J-L, Fruchtman S, Orlowski RZ for the DOXIL-MMY-3001 study investigators. Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 25(8023):446s, 2007.
146. Pamarthi V, Kuhn DJ, Voorhees PM, Strader JS, Orlowski RZ, Chen Q. Kinesin spindle protein inhibition for the treatment of multiple myeloma. Blood 108(1435):124a, 2007.
147. Weaver JA, Brannen C, DeSimone J, Orlowski RZ. Novel nanoparticle-based approaches to target B-cell malignancies. Blood 110(4903):301b, 2007.
148. Kumar S, Blade J, San-Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Sutherland HJ, Robak T, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin in combination with bortezomib may provide therapeutic advantages for high-risk multiple myeloma patients who relapse within 12 months of stem cell transplant. Blood 110(2730):802a, 2007.
149. Stewart AK, O'Connor, OA, Alsina M, Trudel S, Urquilla PR, Vallone MK, Molineaux CJ, Goy A, Orlowski RZ. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 25(8003):441s, 2007.
150. Manges RF, Sutherland HJ, Jagannath SJ, Orlowski RZ, La Police D, DeWitte M, Lang Z, Corringham RE, Rossi JF. Preliminary results of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb), in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 110(1183):358a, 2007.
151. Orlowski RZ, Stewart AK, Vallone MK, Molineauz CJ, Kunkel L, Gericitano J, O'Connor OA. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (R-171) dosed for five consecutive days in hematologic malignancies: Phase I results. Blood 110(409):127a, 2007.
152. Jones RJ, Yang D, Bruey-Sedano N, Orlowski RZ. Targeting the human double minute (HDM)-2 p53 ubiquitin ligase as a strategy against non-Hodgkin lymphoma. Blood 110(1374):413a, 2007.
153. Jones RJ, Leopold L, Yang D, Orlowski RZ. Targeting the human double minute (HM)-2 p53 ubiquitin ligase as a strategy against non-Hodgkin lymphoma. J clin Oncol 25(14016):613s, 2007.
154. Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, Hennessey K, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Blood 110(410):127a, 2007.
155. DuPont, J.A., Euliss, L.E., Orlowski, R.Z., Serody, J., Hahn, K.M., Welch, C.M., Small, G.W., Ferrer, I., and DeSimone, J.M. Applying imprint lithography (PRINT) for the generation of shape-specific, targeted nanocarriers in medicine. American Chemical Society 232nd National Meeting, 9/2006.
156. Orlowski, R.Z. Targeting the ubiquitin-proteasome pathway for treatment of malignant lymphomas: Bortezomib and beyond. 12th Danish Cancer Society Symposium, 9/2006.
157. Euliss, L.E., DuPont, J.A., Welch, C.M., Pisano, E., Lin, W., Small, G.W., Orlowski, R.Z., Serody, J., Hahn, K.M., and DeSimone, J.M. Utilizing the emerging imprint lithography technique (PRINT) for the fabrication of shape-specific organic nanoparticles for applications in nanomedicine. American Chemical Society 232nd National Meeting, 9/2006.
158. Orlowski RZ, Chanan-Khan AA, Zehngebot LM, Watson PR, Peterson BL, Sanford BL, Caligiuri MA, Kelly M, Larson RA for the Cancer and Leukemia Group B. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood 108(797):239a, 2006.
159. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, Kurzrock R. CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) - Preliminary results of subjects with Castlemans disease from a phase 1 study in selected hematological malignancies. Blood 108(2728):771a, 2006.
160. Voorhees PM, Small GW, Kuhn DJ, Chen Q, Hunsucker SA, Coringham R, Garay, CA, Zaki MH, Nemeth J, Orlowski RZ. CNTO328 abrogates glucocorticoid (GC) resistance conferred by interleukin (IL)-6 and the bone marrow microenvironment in multiple myeloma (MM). Blood 108(3473):990a, 2006.
161. Kuhn DJ, Voorhees PM, Chen Q, Strader JS, Bruzzese F, Ciavarri JP, Hu Z, Orlowski RZ. Development of immunoproteasome-specific inhibitors as novel anti-cancer drugs. Blood 108(3458):986a, 2006.
162. Voorhees PM, Small GW, Kuhn DJ, Chen Q, Hunsucker SA, Corringham R, Garay CA, Zaki MH, Nemeth J, Orlowski RZ. Enhancing activity of bortezomib against multiple myeloma (MM) through inhibition of interleukin (IL)-6 signaling: A role for repression of myeloid cell leukemia (Mcl)-1. Blood 108(3414):975a, 2006.
163. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ. Extended follow-up of outcome measures and analysis of prognostic factors in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. J Clin Oncol 24(7617):450S, 2006.
164. Chen Q, Pamarthi V, Kuhn DJ, Voorhees PM, Strader JS, Orlowski RZ. Inhibition of kinesin spindle protein induces apoptosis and overcomes drug resistance in models of multiple myeloma. Blood 108(3425):978a, 2006.
165. O'Connor OA, Orlowski RZ, Alsina M, Stewart AK, Trudel S, Vallone MK, Woo TM, Urquilla PR, Molineaux CJ, Goy A. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies. Blood 108(2430):687a, 2006.
166. Kurzrock R, Voorhees P, Fayad L, Orlowski R, VanRhee F, Furman R, Borghaei H, Zaki M, Prabhakar U, Garay C. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies. J Clin Oncol 24(2513):103S, 2006.
167. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Mendy D, Lopez-Girone A, Plantevin V, Xu W, De Parseval L, Corral LG, Glezer E, Chan K, Mercurio F, Orlowski RZ. Targeting the p27 Kip1 E3 ubiquitin ligase for the treatment of multiple myeloma and other hematological malignancies. Blood 108(372):114a, 2006.
168. Orlowski RZ, Zhuang SH, Parekh T, Xiu L, Harousseau J-L for the DOXIL-MMY-3001 study investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase III study. Blood 108(404):124a, 2006.
169. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Orlowski RZ. The novel, irreversible proteasome inhibitor PR-171 demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma, and overcomes bortezomib resistance. Blood 108(3461):987a, 2006.
170. Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA. Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301. Haematologica 90(s1):151, 2005.
171. Orlowski RZ, Kuhn DJ, Small GW, Michaud C, Orlowski M. Identification of novel inhibitors that specifically target the immunoproteasome, and induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems. Blood 106:76a, 2005.
172. Voorhees PM, Kuhn DJ, Small GW, Strader JS, Corringham R, Zaki MH, Nemeth J, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO328 sensitizes multiple myeloma cells to bortezomib and attenuates proteasome inhibitor-mediated induction of the anti-apoptotic heat shock protein response. Blood 106:452a, 2005.
173. Kuhn DJ, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Orlowski RZ. Potent activity of a novel, irreversible inhibitor of the ubiquitin-proteasome pathway against pre-clinical models of multiple myeloma. Blood 106:452a, 2005.
174. Orlowski RZ, Small GW, Shi YY. 16th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics. Eur J Cancer 2:17, 2004.
175. Fried DB, Morris DE, Shea TC, Orlowski RZ, Van Deventer HW, Mitchell BS. A systematic review evaluating the addition of radiation therapy to chemotherapy for localized aggressive non-Hodgkin’s lymphoma: What is the role for radiotherapy. Blood 104:862a, 2004.
176. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Siegel D, Irwin D, Schuster M, Srkalovic G, Orlowski RZ, Esseltine D, Wen P, Amato A, Anderson KC. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE®). The SUMMIT and CREST Study Group. Hematol J 5(2):S129, 2004.
177. Orlowski RZ, Shi YY, Small GW. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Breast Cancer Res Treat 88(1):S31, 2004.
178. Orlowski RZ, Shi YY, Small GW. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 88(1)(9):S31, 2004. PMID: 17483361.
179. Orlowski RZ, Voorhees PM, Garcia RA, Hall M.D., Adams, J., Esseltine, D.L., Gabriel, D.A., Shea, T.C., Deventer, H.W. Van, Mitchell, B.S., and Dees, E.C. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Hematol J 5(2):S131, 2004.
180. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Hideshima T, Esseltine D-L, Anderson KC. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: An update with additional follow-up. Hematol J 5(2):S103, 2004.
181. Orlowski RZ. The ubiquitin-proteasome pathway as a target for breast cancer therapy. Breast Cancer Res Treat 88(1):S4, 2004.
182. Dees EC, O’Neil BH, Humes EW, Carey LA, Collichio F, Johri A, Graham ML, Orlowski RZ. A Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin. Breast Cancer Res Treat 82(1):84, 2003.
183. Orlowski RZ. Bortezomib-based combination regimens in multiple myeloma. Cancer Invest 22, 2003.
184. Jagannath S, Barlogie B, Berenson J, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Nix D, Guerciolini R, Esseltine D, Anderson KC. Limited experience from two Phase 2 trials suggests bortezomib can be given safely in multiple myeloma patients with severe renal impairment with comparable responses and toxicities. Blood 102:236a, 2003.
185. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar V, Limentani S, Alsina M, Orlowski RZ, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, Anderson KC. Peripheral neuropathy following bortezomib (VELCADE™, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): Characterization and reversibility. Blood 102:149a, 2003.
186. Orlowski RZ, Voorhees PM, Garcia RA, Hall, MD, Hogan CM, Kudrik FJ, Humes E, Johri A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine, D-L, Depcik-Smith ND, Bell H, Lehman MJ, Dees, EC. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Hematology J 4:S254, 2003.
187. Orlowski RZ, Voorhees P, Garcia R, Hall M, Adams J, Esseltine D, Dees EC. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Proc Amer Soc Clin Oncol 22:200, 2003.
188. Orlowski RZ, Voorhees P, Garcia R, Hall M, Lehman M, Johri A, Humes E, Adams J, Esseltine D, Gabriel D, Shea T, van Deventer H, Mitchell B, Dees EC. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 102:449a, 2003.
189. Dees EC, O’Neil B, Humes E, Hall M, Carey L, Collichio F, Graham M, Orlowski RZ. Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc Amer Soc Clin Oncol 22:217, 2003.
190. Jagannath S, Richardson P, Barlogie B, Berenson J, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine D, Anderson K Other authors: Traynor A, Vincent Rajkumar V, Alsina M, Siegel D, Alexanian R, Orlowski RZ, Schuster M, Kuter D, Limentani S, Richards G, Adams J. Phase II trial of bortezomib in combination with dexamethasone in multiple myeloma: Assessment of additional benefits in patients with non-optimal responses. Proc Amer Soc Clin Oncol 22:528, 2003.
191. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Esseltine D, Schenkein DP, Anderson KC Other Authors: Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Richards G, Adams J. Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma treated with bortezomib. Proc Amer Soc Clin Oncol 22:581, 2003.
192. Lee S, Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Schenkein D, Esseltine D, Anderson K, Other authors: Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Richards G, Adams J. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma treated with bortezomib. Proc. Amer. Soc. Clin. Oncol 22:582, 2003.
193. Jagannath S, Richardson P, Barlogie B, Berenson J, Singal S, Siegel D, Irwin D, Schuster M, Rajkumar V, Alexanian R, Srkalovic G, Limentani S, Alsina M, Orlowski RZ, Esseltine D, Anderson K. Results of two multicenter Phase II trials using the proteasome inhibitor bortezomib in relapsed and/or refractory multiple myeloma. Hematol J, 2003.
194. Orlowski RZ. Targeting the proteasome in cancer therapy. Int J Mol Med 12:S61, 2003.

Book Chapters

1. Lee HC, Orlowski RZ. Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. In: Resistance to Proteasome Inhibitors in Cancer. Ed(s) Q Ping Dou, B Bonavida. Springer: New York, 81-98, 2014.

Grant & Contract Support

Title: Modulating Proteasome Load in Conjunction with Proteasome Function in Multiple Myeloma
Funding Source: Amgen
Role: Principal Investigator
Duration: 3/1/2015 - 2/28/2017
 
Title: Targeting the EGFR/JAK/STAT Pathway in Conjunction with Proteasome Inhibition in Multiple Myeloma
Funding Source: Amgen
Role: Principal Investigator
Duration: 3/1/2015 - 2/28/2017
 
Title: Hematological Malignancies
Funding Source: NIH/NCI
Role: Program Leader
Principal Investigator: Ronald DePinho
Duration: 2/1/2015 - 6/30/2018
 
Title: Inhibiting Proteasome Assembly in Conjunction with Proteasome Function
Funding Source: Amgen
Role: Principal Investigator
Duration: 11/11/2014 - 11/10/2016
 
Title: High-Risk Multiple Myeloma Moon Shot Pilot Program
Funding Source: MDACC
Role: Director
Duration: 9/1/2014 - 8/31/2015
 
Title: Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma, Funded, Not Activated
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 8/31/2014 - 8/30/2017
 
Title: Millennium Myeloma Advanced Scholars Program, Funded, Not Activated
Funding Source: Millennium
Role: Principal Investigator
Duration: 7/1/2014 - 6/30/2019
 
Title: Modeling of Filanesib (ARRY-520) Drug Resistance in Multiple Myeloma, Funded, Not Activated
Funding Source: Array BioPharma Inc
Role: Principal Investigator
Duration: 6/30/2014 - 6/29/2016
 
Title: Genome Wide Admixture Scan for Multiple Myeloma in African Americans, Funded, Not Activated
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Wendy Cozen
Duration: 6/1/2014 - 5/31/2015
 
Title: SWOG Network Group Operations of the NCTN, Funded, Not Activated
Funding Source: NIH/NCI
Role: SWOG Chair
Principal Investigator: Charles D. Blanke
Duration: 3/1/2014 - 2/28/2019
 
Title: Mechanisms of Sensitization to Anti-folate Therapeutics, Funded, Not Activated
Funding Source: Spectrum
Role: Principal Investigator
Duration: 2/2/2014 - 2/19/2017
 
Title: Novel Targets in High Risk Multiple Myeloma, Funded, Not Activated
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2015
 
Title: Mechanisms of Immunomodulatory Drug Activity, Resistance, and Sensitization in Myeloma, Funded, Not Activated
Funding Source: Mayo
Role: Principal Investigator
Duration: 4/1/2013 - 3/31/2018
 
Title: Novel approaches targeting high risk deletion 17p Myeloma, Funded, Not Activated
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 12/1/2012 - 11/30/2013
 
Title: Modeling of Carfilzomib and ONX 0912 Drug Resistance in Multiple Myeloma :An Overview of a Proposed Collaboration Between Onyx Pharmaceuticals, Inc., and The University of Texas M. D. Anderson Cancer Center, Funded, Not Activated
Funding Source: Onyx Pharmaceuticals
Role: Principal Investigator
Duration: 9/1/2012 - 9/9/2016
 
Title: Mechanisms of Sensitization to Anti-folate Therapeutics, Funded, Not Activated
Funding Source: Allos
Role: Principal Investigator
Duration: 8/27/2012 - 8/26/2016
 
Title: Onyx Pre-Clinical Trials, Funded, Not Activated
Funding Source: Onyx Pharmaceuticals
Role: Director
Duration: 12/16/2011 - 2/10/2015
 
Title: SWOG, Funded, Not Activated
Funding Source: University of Michigan SWOG
Role: Principal Investigator
Duration: 4/1/2011 - 2/28/2019
 
Title: Modeling of Elotuzumab and Lenalidomide Drug Resistance in Multiple Myeloma, Funded, Not Activated
Funding Source: Bristol Myers Squibb
Role: Principal Investigator
Duration: 4/1/2011 - 1/31/2016
 
Title: Quality of Life and Symptom burden of Myeloma Patients in the Novel Agent Era, Funded, Not Activated
Funding Source: Millennium Pharmaceuticals, Inc
Role: Principal Investigator
Duration: 3/1/2011 - 3/16/2015
 
Title: Genomic studies of drug resistance and toxicity in the novel agent era, Funded, Not Activated
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 3/1/2011 - 2/28/2013
 
Title: Novel Strategies Targeting Proteolysis Applied to Myeloma Induction Therapy, Funded, Not Activated
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2015
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma, Project 3, Targeting the HDM-2 E3 Ligase in Multiple Myeloma, Funded, Not Activated
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/22/2010 - 9/21/2015
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma Administrative Core Facility, Funded, Not Activated
Funding Source: NIH/NCI
Role: Core Facility Director
Duration: 9/22/2010 - 9/21/2015
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma Developmental Research Program, Funded, Not Activated
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/22/2010 - 9/21/2015
 
Title: MD Anderson Cancer Center SPORE in Multiple Myeloma, Funded, Not Activated
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/22/2010 - 8/31/2015
 
Title: A Genome Wide Admixture Scan of Multiple Myeloma in African-Americans, Funded, Not Activated
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Cozen
Duration: 8/1/2010 - 5/31/2015
 
Title: Mechanisms of Lenalidomide Resistance, Funded, Not Activated
Funding Source: MMRF
Role: Principal Investigator
Duration: 6/1/2010 - 6/30/2013
 
Title: Molecular Profiling of Multiple Myeloma at M. D. Anderson, Funded, Not Activated
Funding Source: Millennium Pharmaceuticals, Inc
Role: Principal Investigator
Duration: 3/1/2010 - 2/28/2015
 
Title: Investiqation of Lenalidomide Resistance in Multi le Mveloma, Funded, Not Activated
Funding Source: Celgene
Role: Principal Investigator
Duration: 11/9/2009 - 12/31/2015
 
Title: Mechanisms of Lenalidomide Resistance in Multiple Myeloma, Funded, Not Activated
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 11/1/2009 - 11/30/2012
 
Title: Mechanisms of Symptoms of Multiple Myeloma and its Therapy, Funded, Not Activated
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2009 - 8/31/2013
 
Title: Carolina Center for Nanotechnology Excellence, Project 2: "Smart" Nanoparticles for Cancer Therapy and Imaging, Funded, Not Activated
Funding Source: Carolina Center for Nantechnology
Role: Co-Investigator
Principal Investigator: DeSimone
Duration: 9/1/2005 - 8/31/2010
 
Title: Targeting the Ubiquitin-Proteasome and Heat Shock Pathways as Therapy for Hematologic Malignancies, Funded, Not Activated
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 7/1/2005 - 6/30/2010
 
Title: The Immunoproteasome as a Target for Multiple Myeloma Therapy, Funded, Not Activated
Funding Source: MMRF
Role: Principal Investigator
Duration: 7/1/2005 - 6/30/2006
 
Title: Dual Proteasome and MAPK Inhibition in Cancer Therapy, Funded, Not Activated
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2004 - 8/28/2011
 
Title: SPORE in Breast Cancer, Project 7: Inhibition of Chemotherapy-Induced NF-kB, Funded, Not Activated
Funding Source: NCI
Role: Co-Investigator
Principal Investigator: Earp, ES
Duration: 8/1/2001 - 7/31/2006
 
Title: Spore in Breast Cancer, Project 8: A Novel Chemotherapy for Breast Cancer, Funded, Not Activated
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Earp, ES
Duration: 8/1/2001 - 7/31/2006

Last updated: 5/1/2015